Additionally, the 36-month beta value for XFOR is 0.42. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XFOR is 122.08M and currently, short sellers hold a 10.05% ratio of that float. The average trading volume of XFOR on May 07, 2024 was 3.12M shares.
XFOR) stock’s latest price update
X4 Pharmaceuticals Inc (NASDAQ: XFOR)’s stock price has soared by 4.35 in relation to previous closing price of 1.15. Nevertheless, the company has seen a gain of 10.09% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-30 that BOSTON, April 30, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.
XFOR’s Market Performance
XFOR’s stock has risen by 10.09% in the past week, with a monthly drop of -12.41% and a quarterly rise of 41.41%. The volatility ratio for the week is 8.43% while the volatility levels for the last 30 days are 12.64% for X4 Pharmaceuticals Inc The simple moving average for the last 20 days is -1.23% for XFOR’s stock, with a simple moving average of 15.31% for the last 200 days.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at 4.06% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.40% of loss for the given period.
Volatility was left at 12.64%, however, over the last 30 days, the volatility rate increased by 8.43%, as shares sank -6.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.00% upper at present.
During the last 5 trading sessions, XFOR rose by +10.09%, which changed the moving average for the period of 200-days by -35.83% in comparison to the 20-day moving average, which settled at $1.2105. In addition, X4 Pharmaceuticals Inc saw 43.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Mostafa Adam S., who sale 52,500 shares at the price of $0.88 back on Mar 11 ’24. After this action, Mostafa Adam S. now owns 0 shares of X4 Pharmaceuticals Inc, valued at $46,347 using the latest closing price.
Ragan Paula, the President and CEO of X4 Pharmaceuticals Inc, sale 49,678 shares at $0.88 during a trade that took place back on Mar 11 ’24, which means that Ragan Paula is holding 765,068 shares at $43,856 based on the most recent closing price.
Stock Fundamentals for XFOR
The total capital return value is set at -0.84. Equity return is now at value -161.67, with -66.81 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.64. The debt to equity ratio resting at 1.09. The interest coverage ratio of the stock is -17.89.
Currently, EBITDA for the company is -105.53 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
In conclusion, X4 Pharmaceuticals Inc (XFOR) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
